FLFang Li

Fang Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fang Li has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Analysis of the Current Status of Self-Management Behaviors and Factors Affecting Self-Management in Elderly Empty Nesters with Comorbid Hypertension and Type 2 Diabetes Mellitus, a Cross-Sectional Study From the Community

    by Fang Li, Yuzhong Cao, Xuejuan Xie, Mengwei Li, Tengteng Cheng

    Purpose: This study aimed to investigate disease self-management and its influencing factors among empty nesters with comorbid hypertension and type 2 diabetes mellitus in the Chinese community. Patients and Methods: A questionnaire was administered to 385 empty nesters in the community with comorbid hypertension and type 2 diabetes mellitus, including general information about the patients, the conditions of hypertension and type 2 diabetes mellitus, and self-management scores. The results were analysed using independent samples t-test, one-way ANOVA and multiple linear regression. Results: Disease self-management ability among 360 empty nesters in the community with comorbid hypertension and type 2 diabetes mellitus was low to moderate level. The results of the multiple linear regression analysis showed that age, education, healthcare payment method, and systolic blood pressure were common influences on self-management of the two diseases; hypertension classification, body mass index, and 2-hour postprandial blood glucose were influences on self-management of hypertension; and diabetes treatment method and residence mode were influences on self-management of type 2 diabetes mellitus. Conclusion: Primary healthcare providers need to pay close attention to the self-management skills of empty nesters with comorbid hypertension and type 2 diabetes mellitus in the community, especially in terms of disease monitoring and dietary management. Effective self-management health education, including sustained and effective lifestyle interventions, should be provided as early as possible for those living alone, newly diagnosed, less educated, and with limited healthcare resources, and the addition of elements of Chinese medicine health management, can also be considered to play a role in integrating prevention and treatment.


  • Open Access

    Salinomycin Exerts Anticancer Effects on PC-3 Cells and PC-3-Derived Cancer Stem Cells In Vitro and In Vivo

    by Yunsheng Zhang, Luogen Liu, Fang Li, Tao Wu, Hongtao Jiang, Xianxun Jiang, Xiaobo Du, Yi Wang

    Salinomycin is an antibiotic isolated from Streptomyces albus that selectively kills cancer stem cells (CSCs). However, the antitumor mechanism of salinomycin is unclear. This study investigated the chemotherapeutic efficacy of salinomycin in human prostate cancer PC-3 cells. We found that cytotoxicity of salinomycin to PC-3 cells was stronger than to nonmalignant prostate cell RWPE-1, and exposure to salinomycin induced G2/M phage arrest and apoptosis of PC-3 cells. A mechanistic study found salinomycin suppressed Wnt/β-catenin pathway to induce apoptosis of PC-3 cells. An in vivo experiment confirmed that salinomycin suppressed tumorigenesis in a NOD/SCID mice xenograft model generated from implanted PC-3 cells by inhibiting the Wnt/β-catenin pathway, since the total β-catenin protein level was reduced and the downstream target c-Myc level was significantly downregulated. We also showed that salinomycin, but not paclitaxel, triggered more apoptosis in aldehyde dehydrogenase- (ALDH-) positive PC-3 cells, which were considered as the prostate cancer stem cells, suggesting that salinomycin may be a promising chemotherapeutic to target CSCs. In conclusion, this study suggests that salinomycin reduces resistance and relapse of prostate tumor by killing cancer cells as well as CSCs.


  • Open Access

    G31P, an Antagonist against CXC Chemokine Receptors 1 and 2, Inhibits Growth of Human Prostate Cancer Cells in Nude Mice

    by Xin Liu, Jing Peng, Wenchang Sun, Shufeng Yang, Guoying Deng, Fang Li, Jya-Wei Cheng, John R. Gordon

    Prostate cancer is the most common malignancy in Western countries. Chemokine C-X-C motif receptor 1 (CXCR1) and CXCR2 play a key role in generation and regulation of CXC chemokine signaling. CXCR1 is a receptor for interleukin 8 (IL8), a pro-inflammatory chemokine, and CXCR1/2 are crucially involved in the prostate cancer development and progression. Thus, we generated a high-affinity human CXCR1/CXCR2 inhibitor, CXCL8 (3-72) K11R/G31P, named G31P, which is a synthetic derivative of the human cytokine, IL-8. In this study, we investigated the effects of G31P on regulation of prostate cancer cell growth in vitro and in nude mouse xenografts. Cell viability, adhesion, and wound healing assays were used to assess the effects of G31P on growth, adhesion, and migration of PC-3 human prostate cancer cells in vitro, respectively. Nude mouse xenografts and xenograft implantation assays were performed to determine the effect of G31P on PC-3 cells in vivo. Immunohistochemistry was used to detect gene expression, and fluorescence imaging was used to detect tumor volume and microvessel density in tumor xenografts. The data showed that G31P treatment significantly reduced PC-3 cell viability, adhesion and migration capacity in a dose-dependent manner (up to 100 ng/ml). Additionally, G31P treatment of nude mice suppressed the growth of orthotopically transplanted tumor xenografts. G31P also inhibited tumor tissue vascularization, which was associated with the decreased expression of vascular endothelial growth factor and nuclear transcription factor (NF)-κB in orthotopic xenograft tissues. This study provides evidence that G31P, a CXCR1/2 inhibitor, may effectively control prostate cancer.